Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 766 to 780 of 7679 results

  1. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA901

  2. Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA889)

    NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.

    Sections for TA889

  3. Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)

    NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...

    Sections for TA277

  4. Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) (TA884)

    NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA884

  5. Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

    NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

    Sections for TA149

  6. Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) (TA932)

    NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA932

  7. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) (TA933)

    NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.

    Sections for TA933

  8. Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) (TA936)

    NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. This is because BMS did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA936

  9. Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) (TA940)

    NICE is unable to make a recommendation on ravulizumab (Ultomiris) for treating generalised myasthenia gravis in adults. This is because Alexion Pharma UK withdrew its evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA940

  10. Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)

    NICE is unable to make a recommendation on ravulizumab (Ultomiris) for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder in adults. This is because Alexion Pharma UK withdrew its evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA941

  11. Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

    NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.

    Sections for TA148

  12. Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)

    NICE is unable to make a recommendation on dupilumab (Dupixent) for treating eosinophilic oesophagitis in people 12 years and over. This is because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA938

  13. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.

  14. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

  15. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.